{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bronchiectasis/prescribing-information/doxycycline/","result":{"pageContext":{"chapter":{"id":"8ed4a900-3e69-51c0-8cd5-c2b0bee9bfe2","slug":"doxycycline","fullItemName":"Doxycycline","depth":2,"htmlHeader":"<!-- begin field f681050c-ffc7-4942-a163-da8e0e36d6d1 --><h2>Doxycycline</h2><!-- end field f681050c-ffc7-4942-a163-da8e0e36d6d1 -->","summary":"","htmlStringContent":"<!-- begin item 84afedb5-6824-4d48-bdec-87672f245817 --><!-- end item 84afedb5-6824-4d48-bdec-87672f245817 -->","topic":{"id":"96a8622b-46f5-55fa-b729-6748e3d98c98","topicId":"26fab339-e333-44ec-a481-de87a29052f3","topicName":"Bronchiectasis","slug":"bronchiectasis","lastRevised":"Last revised in January 2021","chapters":[{"id":"43d88c30-f768-5e1c-a6ea-5596c5577fb5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ac4fde9a-5fd3-5ed9-9201-f714bda470bb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0b34af83-d49a-5145-8589-e8748b8646c0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"04eeb1ae-4fc3-5418-83a2-b62587d8bdda","slug":"changes","fullItemName":"Changes"},{"id":"dbd8ad5a-871c-59b8-9729-444e11ac9df1","slug":"update","fullItemName":"Update"}]},{"id":"b89644c6-805f-50b4-991d-36bb2b0fbf67","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d38de329-73b8-5fed-83ef-f836b765cd3f","slug":"goals","fullItemName":"Goals"},{"id":"3c116665-5586-5551-909c-0efc1ef0be62","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"60e13bc0-e351-5c39-b8ff-9a8d4514bf16","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ee37cc0-9ff4-5bbd-ab3f-0a30cb904bb5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d155aa4f-7dfe-575d-a7dd-a87774f4cbad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"07c3e24b-c950-516e-9070-5441a07b3791","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5146c866-f0a7-54a6-a5ac-8aff4b385cc6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e2107a7e-b7c3-5ba9-94e4-6217ea79a3f2","slug":"definition","fullItemName":"Definition"},{"id":"39df7c47-de08-57ae-aa40-89a7d4d7b031","slug":"causes","fullItemName":"Causes"},{"id":"ac4d346e-97d4-5d84-a704-fbdcf56be7f4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e07a8b0b-866c-5789-85ef-020a5b19b620","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"ef5c5e7b-3cf4-5939-85e0-b61cae41f945","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ce267b5b-70dd-52bd-ad83-6123bd42fa0d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c605c0b9-0519-50e1-abd8-2dc47de7278a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"23a1627d-30f7-5ba4-95f8-060faf797f51","slug":"suspected-infective-exacerbation-diagnosis","fullItemName":"Suspected infective exacerbation diagnosis"}]},{"id":"5a5846fa-c8b4-5cd4-b2d3-770c3dc00ba2","fullItemName":"Management","slug":"management","subChapters":[{"id":"0180d43c-dd8d-5a87-915c-629542f782fe","slug":"suspected-bronchiectasis","fullItemName":"Scenario: Suspected bronchiectasis"},{"id":"290c51ae-6521-5c03-b12e-117e40c88883","slug":"infective-exacerbation","fullItemName":"Scenario: Infective exacerbation"},{"id":"1e90ec28-8eea-5ab7-ac76-2df1ace279de","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6db0266e-4d15-5eec-b2c0-ed20f472eeb5","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"a98b5813-5589-5247-9c65-e9ae534d88c2","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"04c99c8f-7a1d-55f0-85a2-6d0e1bc3e4e3","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"26b521e3-9c5e-5a7c-956b-7f3f39f2e58c","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"6cd6079a-be84-5279-9d10-e3bf4653c049","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"8ed4a900-3e69-51c0-8cd5-c2b0bee9bfe2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"5217d027-064d-5543-93b0-7e8bb1a1c0fc","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cf1fbf18-e60a-54f7-bbc4-2a30ab37f565","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8e888abe-cb05-5343-b6e3-547dea7312cc","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"}]},{"id":"118b4e08-e6ae-510a-b2f5-51b109ef3395","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ecf8de37-d8f0-5ced-af38-9be20fa73de9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1c227675-02ea-5c9e-a927-e385987adf53","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f74bbe64-1998-528f-b811-df2a14219de7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a925d45-6865-5cd5-9624-23da53ee221a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a6ff3076-9be6-55b4-b373-f40cb3045f2c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67608f46-5eba-58f9-86e3-0e0e3f57d921","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3fae7f8d-20fb-5fe6-af57-64882afceb3a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6290a7ff-a800-5322-81b3-c3643cca2d43","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 648ebcda-39c7-4b13-a3f1-d6be93306b8a --><h3>What contraindications and cautions are associated with doxycycline?</h3><!-- end field 648ebcda-39c7-4b13-a3f1-d6be93306b8a -->","summary":"","htmlStringContent":"<!-- begin item e892a78f-b6b7-4e15-b630-89283883440e --><!-- begin field a3e55aeb-0172-435e-8a81-b727407a8afd --><ul><li><strong>Do not prescribe doxycycline to:</strong><ul><li>Pregnant or breastfeeding women.</li><li>Children under 12 years of age.</li></ul></li><li><strong>Prescribe doxycycline with caution to children aged 8–11 years and people with:</strong><ul><li>Alcohol dependence.</li><li>Hepatic impairment. </li><li>Renal impairment.</li><li>Systemic lupus erythematosus.</li><li>Myasthenia gravis.</li></ul></li></ul><div>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>]</div><!-- end field a3e55aeb-0172-435e-8a81-b727407a8afd --><!-- end item e892a78f-b6b7-4e15-b630-89283883440e -->","subChapters":[]},{"id":"8f91eee3-c783-558a-a9b8-f92d179dd20a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 76440a3b-77cc-4b78-974e-998caf7fc653 --><h3>What are the adverse effects of doxycycline?</h3><!-- end field 76440a3b-77cc-4b78-974e-998caf7fc653 -->","summary":"","htmlStringContent":"<!-- begin item 99f2387a-f326-45b3-91e5-9e984dddf26c --><!-- begin field faa63b7f-cc09-4283-a0a1-7fdbae6de088 --><ul><li><strong>Blood disorders</strong> — haemolytic anaemia, thrombocytopenia, neutropenia, eosinophilia (frequency unknown).</li><li><strong>Gastrointestinal</strong> — nausea, vomiting (common), dyspepsia (uncommon), abdominal discomfort, diarrhoea, tooth discolouration and enamel hypoplasia in children (frequency unknown).<ul><li><strong>Rarely:</strong> dysphagia, oesophagitis, oesophageal irritation, pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Hepatic disorders</strong> — hepatotoxicity, hepatitis, jaundice, hepatic failure (frequency unknown).</li><li><strong>Renal disorders</strong> — blood urea increased.</li><li><strong>Skin</strong> — photosensitivity, rash (common).<ul><li><strong>Rarely:</strong> toxic epidermal necrolysis, Stevens–Johnson syndrome, angioedema, erythema multiforme, exfoliative dermatitis, drug reaction with eosinophilia and systemic symptoms (DRESS).</li></ul></li><li><strong>Other rare adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Arthralgia, myalgia.</li><li>Bulging fontanelles in infants.</li><li>Flushing.</li><li>Severe headache and/or visual disturbances — may be an early symptom of benign intracranial hypertension, a rare but serious adverse effect.</li><li>Tinnitus.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2020g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field faa63b7f-cc09-4283-a0a1-7fdbae6de088 --><!-- end item 99f2387a-f326-45b3-91e5-9e984dddf26c -->","subChapters":[]},{"id":"8db5e9b6-6569-5e00-bf83-04cf7aa231d2","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 56be40db-0000-48da-9f31-a0e48ea4df12 --><h3>What drug interactions are important with doxycycline?</h3><!-- end field 56be40db-0000-48da-9f31-a0e48ea4df12 -->","summary":"","htmlStringContent":"<!-- begin item 9bd4fabd-18f0-44d1-9a4d-26ff8d578a30 --><!-- begin field e4143500-40fc-4bda-a020-270ba09727f6 --><ul><li><strong>Antacids (containing aluminium, bismuth, calcium, or magnesium) and other medications containing iron or zinc </strong>— these reduce the absorption of tetracyclines if taken concurrently.<ul><li>Avoid taking antacids and other medications containing iron or zinc, 2 hours before or after taking tetracyclines.</li></ul></li><li><strong>CYP3A enzyme inducers</strong> (phenobarbital, carbamazepine, or phenytoin) — these may reduce the serum half-life of doxycycline. Monitor and adjust the dose if necessary.</li><li><strong>Insulin </strong>— the blood-glucose lowering effect may be increased if taken with doxycycline. Monitor blood-glucose levels.</li><li><strong>Lithium</strong> — levels may be increased by doxycycline. Consider increasing the frequency of lithium monitoring.</li><li><strong>Methotrexate</strong> — levels may be increased by doxycycline.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of doxycycline.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Retinoids </strong>— there is a possible increased risk of benign intracranial pressure if tetracyclines are used concurrently with retinoids (such as isotretinoin).<ul><li>Avoid the concurrent use of tetracyclines and retinoids.</li></ul></li><li><strong>Rifampicin</strong> — doxycycline levels are markedly reduced, which may lead to treatment failure. Monitor the effects and increase doxycycline dose if necessary.</li><li><strong>Typhoid vaccine </strong>— antibacterials might reduce the immune response. The World Health Organization (WHO) recommends that the antibacterial is stopped from 3 days before to 3 days after receiving live oral typhoid vaccine.</li><li><strong>Warfarin </strong>— the concurrent use of warfarin with tetracyclines may increase the anticoagulant effect. However, there is little evidence to suggest clinical relevance.<ul><li>Consider monitoring the person's international normalized ratio (INR) regularly and within 3 days of starting the tetracycline. Adjust the warfarin dose accordingly.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">FSRH, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Preston, 2020</a>]</p><!-- end field e4143500-40fc-4bda-a020-270ba09727f6 --><!-- end item 9bd4fabd-18f0-44d1-9a4d-26ff8d578a30 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}